Zobrazeno 41 - 50
of 101
pro vyhledávání: '"Angelica M. Gutierrez Barrera"'
Publikováno v:
International Journal of Oncology
PARP inhibitors are considered promising anti-cancer agents and currently being tested in clinical trials in hereditary breast cancer patients harboring mutations in BRCA1 and BRCA2 genes. In this study, we investigated the antiproliferative effects
Autor:
Michelle Jackson, Ashley H. Woodson, Funda Meric-Bernstam, Karen H. Lu, Amanda C. Brandt, Jennifer K. Litton, Angelica M. Gutierrez-Barrera, Soley Bayraktar, Banu Arun, Diane Liu, Vicente Valero
Publikováno v:
The Breast Journal. 21:260-267
The genotype-phenotype correlations of the specific BRCA1 and BRCA2 mutations in multi-ethnic populations in USA have not yet been fully investigated. This study was designed to evaluate the effects of ethnicity at specific mutation locations and bre
Autor:
Michael Gambello, Christopher I. Amos, S. Shahrukh Hashmi, Laura M. Amendola, Angelica M. Gutierrez-Barrera, Banu Arun, Kaylene Ready, Soley Bayraktar
Publikováno v:
The Breast. 23:770-774
Breast cancer diagnosed in women 35 years of age or less accounts for2% of all breast cancer cases. Clinical and pathologic characteristics of early onset breast cancer are not well defined in BRCA mutation carriers and non-carriers.194 women diagnos
Autor:
Angelica M. Gutierrez-Barrera, Susan K. Peterson, Juhee Song, Gustavo Schvartsman, Naoto T. Ueno, Banu Arun
Publikováno v:
Cancer Medicine
Obese and overweight women have an increased risk of breast cancer and worse outcomes at the time of diagnosis. Women tend to gain weight after breast cancer diagnosis and during chemotherapy for early‐stage disease, which may in turn increase risk
Autor:
Shane R. Stecklein, Diane D. Liu, Simona F. Shaitelman, Wendy A. Woodward, Banu Arun, Gabriel O. Sawakuchi, Bhavana V. Chapman, Angelica M. Gutierrez Barrera
Publikováno v:
Journal of Clinical Oncology. 37:1502-1502
1502 Background: Women with germline mutations in DNA repair pathways are at an increased risk of developing breast cancer. We posit that tumors arising in these patients may be more sensitive to radiotherapy and, therefore, patients may experience i
Autor:
Ashley H. Woodson, Michelle Jackson, Angelica M. Gutierrez-Barrera, Banu Arun, Kimberly I. Muse, Jennifer K. Litton, Henry Mark Kuerer, George Baum, Nisreen Elsayegh, P Jessica
Publikováno v:
Cancer Research. 73:P5-13
Background: The rate of prophylactic mastectomy (PM) has recently increased1. A deleterious mutation in the BRCA1 or BRCA 2 genes is among the major reasons why patients pursue PM 2, 3. Women with BRCA1 or BRCA2 gene mutations have up to an 87% risk
Autor:
Swati Biswas, Banu Arun, Angelica M. Gutierrez Barrera, Philamer Atienza, Kevin S. Hughes, Giovanni Parmigiani, Christopher I. Amos, Jonathan Chipman
Publikováno v:
Breast Cancer Research and Treatment. 139:571-579
Health care providers need simple tools to identify patients at genetic risk of breast and ovarian cancers. Genetic risk prediction models such as BRCAPRO could fill this gap if incorporated into Electronic Medical Records or other Health Information
Autor:
Kelly K. Hunt, Jennifer K. Litton, Gabriel N. Hortobagyi, Banu Arun, Diane Liu, Soley Bayraktar, Lajos Pusztai, Fraser Symmans, Angelica M. Gutierrez Barrera, Vicente Valero, Yun Wu
Publikováno v:
The Cancer Journal. 19:10-17
PURPOSE USP-11, a member of the ubiquitin-specific protease family, has emerged as an essential regulator of double-strand break repair. Few studies have shown that silencing USP-11 led to hypersensitivity to poly(ADP-ribose) polymerase inhibition, i
Autor:
Massimo Cristofanilli, I. Kiyokawa, JM Reuben, V. Valero, Angelica M. Gutierrez-Barrera, Ricardo H. Alvarez, NT Ueno, B-N Lee, S Tin, Banu Arun, T. Miura, Evan N. Cohen
Publikováno v:
Cancer Research. 72:P2-10
Background: Cytokines and chemokines are known to be involved in tumor growth and progression of disease. Sialyl LewisX (sLeX), a ligand for adhesion molecule E-selectin, is known to affect inflammatory processes and an elevated level is associated w
Autor:
Diane Liu, Scott M. Lippman, Terri L. Cornelison, Ricardo R. Alvarez, Jennifer K. Litton, Angelica M. Gutierrez-Barrera, James L. Murray, Banu Arun, Powel H. Brown, Gabriel N. Hortobagyi, Nour Sneige, Yun Gong, Kimberly B. Koenig, J. Jack Lee, Brandy M. Heckman-Stoddard, Nuhad K. Ibrahim, Lana Vornik, Vicente Valero
Publikováno v:
Breast cancer research and treatment, vol 158, iss 1
Selective estrogen receptor modulators (SERMs), tamoxifen, and raloxifene that reduce the risk of breast cancer are limited to only estrogen receptor-positive (ER(+)) breast cancer. In addition, patient acceptance of SERMs is low due to toxicity and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88b687ceb8dde7a4eb4b997dedac0d86
https://europepmc.org/articles/PMC5989315/
https://europepmc.org/articles/PMC5989315/